O
ABMD

OppenheimerFunds’s Abiomed Inc ABMD Stock Holding History

OppenheimerFunds’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$25.6M Buy
89,678
+4,821
+6% +$1.6M 0.03% 477
2018
Q4 		$27.6M Buy
84,857
+13,919
+20% +$4.84M 0.04% 431
2018
Q3 		$31.9M Sell
70,938
-3,945
-5% -$1.56M 0.04% 459
2018
Q2 		$30.6M Sell
74,883
-174,624
-70% -$63.3M 0.04% 462
2018
Q1 		$72.6M Sell
249,507
-60,473
-20% -$15.3M 0.09% 242
2017
Q4 		$58.1M Sell
309,980
-9,113
-3% -$1.7M 0.07% 284
2017
Q3 		$53.8M Sell
319,093
-3,569
-1% -$540K 0.07% 293
2017
Q2 		$46.2M Buy
322,662
+75,290
+30% +$10.1M 0.06% 318
2017
Q1 		$31M Buy
247,372
+33,194
+15% +$3.85M 0.04% 438
2016
Q4 		$24.1M Buy
214,178
+917
+0.4% +$106K 0.03% 519
2016
Q3 		$27.4M Buy
213,261
+14,000
+7% +$1.68M 0.03% 492
2016
Q2 		$21.8M Buy
199,261
+7,544
+4% +$751K 0.03% 533
2016
Q1 		$18.2M Buy
191,717
+43,434
+29% +$3.67M 0.02% 598
2015
Q4 		$13.4M Sell
148,283
-23,027
-13% -$1.95M 0.02% 681
2015
Q3 		$15.9M Buy
+171,310
New +$15.1M 0.02% 612

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

OppenheimerFunds's ABMD Position: Q1 2019 in Review

OppenheimerFunds increased its Abiomed Inc (ABMD) stake by 5.7% in Q1 2019, buying an estimated $1.6M and bringing the position to 89,678 shares worth $25.6M. The position accounts for 0.03% of the portfolio, ranked #477.

OppenheimerFunds first reported a position in ABMD in Q3 2015 and has held it in 15 quarters since. The position peaked at $72.6M in Q1 2018. 559 funds tracked by Wall St. Rank hold ABMD as of Q1 2019.

  • OppenheimerFunds held 89,678 shares of Abiomed Inc worth $25.6M as of Q1 2019.
  • OppenheimerFunds bought 4,821 Abiomed Inc shares in Q1 2019, an estimated $1.6M.
  • Abiomed Inc made up 0.03% of OppenheimerFunds's portfolio in Q1 2019, its #477 holding.
  • OppenheimerFunds first reported a position in Abiomed Inc in Q3 2015 and has held it in 15 quarters since.
  • OppenheimerFunds's Abiomed Inc position peaked at $72.6M in Q1 2018.
  • 559 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.